Immutep’s EFTISARC-NEO Trial Shows Promising Results in Soft Tissue Sarcoma
Immutep Ltd (AU:IMM) announced promising results from its EFTISARC-NEO Phase II trial for soft tissue sarcoma, presented at the CTOS 2025 Annual Meeting. The trial showed significant tumor hyalinization/fibrosis with a combination of eftilagimod alfa, radiotherapy, and KEYTRUDA, indicating a strong immune response and potential for improved patient outcomes. The latest analyst rating for AU:IMM is a Hold with a price target of A$0.50. Immutep focuses on immunotherapy for cancer and autoimmune diseases, with a current market cap of A$375.3M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Immutep Ltd ( (AU:IMM) ).
Immutep Limited announced promising results from its EFTISARC-NEO Phase II trial, which were presented at the CTOS 2025 Annual Meeting. The trial demonstrated significant tumor hyalinization/fibrosis in patients with soft tissue sarcoma (STS) using a novel combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA. This combination showed a strong immune response, potentially leading to better patient outcomes and survival rates. The findings suggest that efti could be beneficial in treating early-stage cancers, expanding its role in the cancer treatment landscape.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a late-stage immunotherapy company focused on targeting cancer and autoimmune diseases. The company is involved in developing treatments that activate the immune system to fight these conditions.
Average Trading Volume: 2,426,896
Technical Sentiment Signal: Sell
Current Market Cap: A$375.3M
Learn more about IMM stock on TipRanks’ Stock Analysis page.
